Top

Published in:

01-09-2019 | Alzheimer's Disease | Review Paper

Beneficial Effects of Fingolimod in Alzheimer’s Disease: Molecular Mechanisms and Therapeutic Potential

Authors: Efthalia Angelopoulou, Christina Piperi

Published in: NeuroMolecular Medicine | Issue 3/2019

Abstract

Alzheimer’s disease (AD), the most common cause of dementia remains of unclear etiology with current pharmacological therapies failing to halt disease progression. Several pathophysiological mechanisms have been implicated in AD pathogenesis including amyloid-β protein (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation and alterations in bioactive lipid metabolism. Sphingolipids, such as sphingosine-1-phosphate (S1P) and intracellular ceramide/S1P balance are highly implicated in central nervous system physiology as well as in AD pathogenesis. FTY720/Fingolimod, a structural sphingosine analog and S1P receptor (S1PR) modulator that is currently used in the treatment of relapsing–remitting multiple sclerosis (RRMS) has been shown to exert beneficial effects on AD progression. Recent in vitro and in vivo evidence indicate that fingolimod may suppress Aβ secretion and deposition, inhibit apoptosis and enhance brain-derived neurotrophic factor (BDNF) production. Furthermore, it regulates neuroinflammation, protects against N-methyl-d-aspartate (NMDA)-excitotoxicity and modulates receptor for advanced glycation end products signaling axis that is highly implicated in AD pathogenesis. This review discusses the underlying molecular mechanisms of the emerging neuroprotective role of fingolimod in AD and its therapeutic potential, aiming to shed more light on AD pathogenesis as well as direct future treatment strategies.

Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012). Alzheimer’s disease: A clinical practice-oriented review. Frontiers in Neurology, 3, 63. https://doi.org/10.3389/fneur.2012.00063.CrossRefPubMedPubMedCentral

Asle-Rousta, M., Kolahdooz, Z., Dargahi, L., Ahmadiani, A., & Nasoohi, S. (2014). Prominence of central sphingosine-1-phosphate receptor-1 in attenuating abeta-induced injury by fingolimod. Journal of Molecular Neuroscience, 54(4), 698–703. https://doi.org/10.1007/s12031-014-0423-3.CrossRefPubMed

Asle-Rousta, M., Kolahdooz, Z., Oryan, S., Ahmadiani, A., & Dargahi, L. (2013). FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats. Journal of Molecular Neuroscience, 50(3), 524–532. https://doi.org/10.1007/s12031-013-9979-6.CrossRefPubMed

Aytan, N., Choi, J. K., Carreras, I., Brinkmann, V., Kowall, N. W., Jenkins, B. G., et al. (2016). Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer’s disease. Scientific Reports, 6, 24939. https://doi.org/10.1038/srep24939.CrossRefPubMedPubMedCentral

Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., et al. (2011). Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimer’s Research & Therapy, 3(1), 1. https://doi.org/10.1186/alzrt59.CrossRef

Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012). Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Archieves of Neurology, 69(7), 901–905. https://doi.org/10.1001/archneurol.2011.3758.CrossRef

Bianca, V. D., Dusi, S., Bianchini, E., Dal Pra, I., & Rossi, F. (1999). Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease. The Journal of Biological Chemistry, 274(22), 15493–15499. https://doi.org/10.1074/jbc.274.22.15493.CrossRefPubMed

Brinkmann, V., Pinschewer, D. D., Feng, L., & Chen, S. (2001). FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation, 72(5), 764–769.CrossRef

Cannavo, A., Liccardo, D., Komici, K., Corbi, G., de Lucia, C., Femminella, G. D., et al. (2017). Sphingosine kinases and sphingosine 1-phosphate receptors: Signaling and actions in the cardiovascular system. Frontiers in Pharmacology, 8, 556. https://doi.org/10.3389/fphar.2017.00556.CrossRefPubMedPubMedCentral

Ceccom, J., Loukh, N., Lauwers-Cances, V., Touriol, C., Nicaise, Y., Gentil, C., et al. (2014). Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease. Acta Neuropathologica Communications, 2, 12. https://doi.org/10.1186/2051-5960-2-12.CrossRefPubMedPubMedCentral

Chakrabarti, S. S., Bir, A., Poddar, J., Sinha, M., Ganguly, A., & Chakrabarti, S. (2016). Ceramide and sphingosine-1-phosphate in cell death pathways: Relevance to the pathogenesis of alzheimer’s disease. Current Alzheimer Research, 13(11), 1232–1248. https://doi.org/10.2174/1567205013666160603004239.CrossRefPubMed

Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C. W., Noguchi, K., et al. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proceedings of the National academy of Sciences of the United States of America, 108(2), 751–756. https://doi.org/10.1073/pnas.1014154108.CrossRefPubMed

Chu, J., Lauretti, E., & Pratico, D. (2017). Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3beta kinase: Implications for Alzheimer’s disease. Molecular Psychiatry, 22(7), 1002–1008. https://doi.org/10.1038/mp.2016.214.CrossRefPubMed

Clausznitzer, D., Pichardo-Almarza, C., Relo, A. L., van Bergeijk, J., van der Kam, E., Laplanche, L., et al. (2018). Quantitative systems pharmacology model for alzheimer disease indicates targeting sphingolipid dysregulation as potential treatment option. CPT Pharmacometrics & Systems Pharmacology, 7(11), 759–770. https://doi.org/10.1002/psp4.12351.CrossRef

Collister, K. A., & Albensi, B. C. (2005). Potential therapeutic targets in the NF-kappaB pathway for Alzheimer’s disease. Drug News & Perspectives, 18(10), 623–629. https://doi.org/10.1358/dnp.2005.18.10.959576.CrossRef

Colombo, E., Di Dario, M., Capitolo, E., Chaabane, L., Newcombe, J., Martino, G., et al. (2014). Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Annals of Neurology, 76(3), 325–337. https://doi.org/10.1002/ana.24217.CrossRefPubMed

Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., et al. (2014). Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathologica Communications, 2, 9. https://doi.org/10.1186/2051-5960-2-9.CrossRefPubMedPubMedCentral

Cruickshanks, N., Roberts, J. L., Bareford, M. D., Tavallai, M., Poklepovic, A., Booth, L., et al. (2015). Differential regulation of autophagy and cell viability by ceramide species. Cancer Biology & Therapy, 16, 733–742. https://doi.org/10.1080/15384047.2015.1026509.CrossRef

Cui, Y., Le, Y., Yazawa, H., Gong, W., & Wang, J. M. (2002). Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer’s disease. Journal of Leukocyte Biology, 72(4), 628–635.PubMed

Cummings, J., Gould, H., & Zhong, K. (2012). Advances in designs for Alzheimer’s disease clinical trials. American Journal of Neurodegenerative Disease, 1(3), 205–216.PubMedPubMedCentral

Cunha, C., Brambilla, R., & Thomas, K. L. (2010). A simple role for BDNF in learning and memory? Frontiers in Molecular Neuroscience, 3, 1. https://doi.org/10.3389/neuro.02.001.2010.CrossRefPubMedPubMedCentral

Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., et al. (2004). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proceedings of the National academy of Sciences of the United States of America, 101(7), 2070–2075. https://doi.org/10.1073/pnas.0305799101.CrossRefPubMedPubMedCentral

Czech, B., Pfeilschifter, W., Mazaheri-Omrani, N., Strobel, M. A., Kahles, T., Neumann-Haefelin, T., et al. (2009). The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochemical and Biophysical Research Communications, 389(2), 251–256. https://doi.org/10.1016/j.bbrc.2009.08.142.CrossRefPubMed

Czubowicz, K., Jesko, H., Wencel, P., Lukiw, W. J., & Strosznajder, R. P. (2019). The role of ceramide and sphingosine-1-phosphate in Alzheimer’s disease and other neurodegenerative disorders. Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1448-3.CrossRefPubMedPubMedCentral

Di Menna, L., Molinaro, G., Di Nuzzo, L., Riozzi, B., Zappulla, C., Pozzilli, C., et al. (2013). Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacological Research, 67(1), 1–9. https://doi.org/10.1016/j.phrs.2012.10.004.CrossRefPubMed

Doi, Y., Takeuchi, H., Horiuchi, H., Hanyu, T., Kawanokuchi, J., Jin, S., et al. (2013). Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS ONE, 8(4), e61988. https://doi.org/10.1371/journal.pone.0061988.CrossRefPubMedPubMedCentral

Dominguez, G., Maddelein, M. L., Pucelle, M., Nicaise, Y., Maurage, C. A., Duyckaerts, C., et al. (2018). Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain. Acta Neuropathologica Communications, 6(1), 25. https://doi.org/10.1186/s40478-018-0527-z.CrossRefPubMedPubMedCentral

Dong, X. X., Wang, Y., & Qin, Z. H. (2009). Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacologica Sinica, 30(4), 379–387. https://doi.org/10.1038/aps.2009.24.CrossRefPubMedPubMedCentral

Efstathopoulos, P., Kourgiantaki, A., Karali, K., Sidiropoulou, K., Margioris, A. N., Gravanis, A., et al. (2015). Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory. Translational Psychiatry, 5, e685. https://doi.org/10.1038/tp.2015.179.CrossRefPubMedPubMedCentral

Fukumoto, K., Mizoguchi, H., Takeuchi, H., Horiuchi, H., Kawanokuchi, J., Jin, S., et al. (2014). Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment. Behavioural Brain Research, 268, 88–93. https://doi.org/10.1016/j.bbr.2014.03.046.CrossRefPubMed

Gomez-Brouchet, A., Pchejetski, D., Brizuela, L., Garcia, V., Altie, M. F., Maddelein, M. L., et al. (2007). Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Molecular Pharmacology, 72(2), 341–349. https://doi.org/10.1124/mol.106.033738.CrossRefPubMed

Groves, A., Kihara, Y., & Chun, J. (2013). Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. Journal of the Neurological Sciences, 328(1–2), 9–18. https://doi.org/10.1016/j.jns.2013.02.011.CrossRefPubMedPubMedCentral

Hagen, N., Hans, M., Hartmann, D., Swandulla, D., & van Echten-Deckert, G. (2011). Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death and Differantiation, 18(8), 1356–1365. https://doi.org/10.1038/cdd.2011.7.CrossRef

Hait, N. C., Wise, L. E., Allegood, J. C., O’Brien, M., Avni, D., Reeves, T. M., et al. (2014). Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nature Neuroscience, 17(7), 971–980. https://doi.org/10.1038/nn.3728.CrossRefPubMedPubMedCentral

Haughey, N. J. (2010). Sphingolipids in neurodegeneration. Neuromolecular Medicine, 12(4), 301–305. https://doi.org/10.1007/s12017-010-8135-5.CrossRefPubMedPubMedCentral

He, X., Huang, Y., Li, B., Gong, C. X., & Schuchman, E. H. (2010). Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiology of Aging, 31(3), 398–408. https://doi.org/10.1016/j.neurobiolaging.2008.05.010.CrossRefPubMed

Hemmati, F., Dargahi, L., Nasoohi, S., Omidbakhsh, R., Mohamed, Z., Chik, Z., et al. (2013). Neurorestorative effect of FTY720 in a rat model of Alzheimer’s disease: Comparison with memantine. Behavioural Brain Research, 252, 415–421. https://doi.org/10.1016/j.bbr.2013.06.016.CrossRefPubMed

Hensley, K. (2010). Neuroinflammation in Alzheimer’s disease: Mechanisms, pathologic consequences, and potential for therapeutic manipulation. Journal of Alzheimers Disease: JAD, 21(1), 1–14. https://doi.org/10.3233/JAD-2010-1414.CrossRefPubMed

Hoffmann, F. S., Hofereiter, J., Rubsamen, H., Melms, J., Schwarz, S., Faber, H., et al. (2015). Fingolimod induces neuroprotective factors in human astrocytes. Journal of Neuroinflammation, 12, 184. https://doi.org/10.1186/s12974-015-0393-6.CrossRefPubMedPubMedCentral

Hohsfield, L. A., & Humpel, C. (2015). Migration of blood cells to beta-amyloid plaques in Alzheimer’s disease. Experimental Gerontology, 65, 8–15. https://doi.org/10.1016/j.exger.2015.03.002.CrossRefPubMedPubMedCentral

Hollands, C., Bartolotti, N., & Lazarov, O. (2016). Alzheimer’s disease and hippocampal adult neurogenesis. Exploring shared mechanisms. Frontiers in Neuroscience, 10, 178. https://doi.org/10.3389/fnins.2016.00178.CrossRefPubMedPubMedCentral

Holmes, C., El-Okl, M., Williams, A. L., Cunningham, C., Wilcockson, D., & Perry, V. H. (2003). Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 74(6), 788–789. https://doi.org/10.1136/jnnp.74.6.788.CrossRefPubMed

Hunter, S. F., Bowen, J. D., & Reder, A. T. (2016). The direct effects of Fingolimod in the central nervous system: Implications for relapsing multiple Sclerosis. CNS Drugs, 30(2), 135–147. https://doi.org/10.1007/s40263-015-0297-0.CrossRef

Huwiler, A., & Zangemeister-Wittke, U. (2017). The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives. Pharmacology & Therapeutics, 185, 34–49. https://doi.org/10.1016/j.pharmthera.2017.11.001.CrossRef

Jackson, S. J., Giovannoni, G., & Baker, D. (2011). Fingolimod modulates microglial activation to augment markers of remyelination. Journal of Neuroinflammation, 8, 76. https://doi.org/10.1186/1742-2094-8-76.CrossRefPubMedPubMedCentral

Jesko, H., Wencel, P. L., Lukiw, W. J., & Strosznajder, R. P. (2018). Modulatory effects of Fingolimod (FTY720) on the expression of sphingolipid metabolism-related genes in an animal model of Alzheimer’s disease. Molecular Neurobiology, 56(1), 174–185. https://doi.org/10.1007/s12035-018-1040-x.CrossRefPubMedPubMedCentral

Jesko, H., Stepien, A., Lukiw, W. J., & Strosznajder, R. P. (2019). The cross-talk between Sphingolipids and insulin-like growth factor signaling: Significance for aging and neurodegeneration. Molecular Neurobiology, 56(5), 3501–3521. https://doi.org/10.1007/s12035-018-1286-3.CrossRefPubMed

Jiao, S. S., Shen, L. L., Zhu, C., Bu, X. L., Liu, Y. H., Liu, C. H., et al. (2016). Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Translational Psychiatry, 6(10), e907. https://doi.org/10.1038/tp.2016.186.CrossRefPubMedPubMedCentral

Kaneider, N. C., Kaser, A., Dunzendorfer, S., Tilg, H., & Wiedermann, C. J. (2003). Sphingosine kinase-dependent migration of immature dendritic cells in response to neurotoxic prion protein fragment. Journal of Virology, 77(9), 5535–5539. https://doi.org/10.1128/JVI.77.9.5535-5539.2003.CrossRefPubMedPubMedCentral

Kaneider, N. C., Lindner, J., Feistritzer, C., Sturn, D. H., Mosheimer, B. A., Djanani, A. M., et al. (2004). The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18(11), 1309–1311. https://doi.org/10.1096/fj.03-1050fje.CrossRef

Karaca, I., Tamboli, I. Y., Glebov, K., Richter, J., Fell, L. H., Grimm, M. O., et al. (2014). Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. Journal of Biological Chemistry, 289(24), 16761–16772. https://doi.org/10.1074/jbc.M113.535500.CrossRefPubMed

Lahiri, S., Park, H., Laviad, E. L., Lu, X., Bittman, R., & Futerman, A. H. (2009). Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. Journal of Biological Chemistry, 284(24), 16090–16098. https://doi.org/10.1074/jbc.M807438200.CrossRefPubMed

Li, Y., Li, S., Qin, X., Hou, W., Dong, H., Yao, L., et al. (2014). The pleiotropic roles of sphingolipid signaling in autophagy. Cell Death and Disease, 22, e1245. https://doi.org/10.1038/cddis.2014.215.CrossRef

Lorton, D. (1997). beta-Amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent. Mechanisms of Ageing and Development, 94(1–3), 199–211.CrossRef

Mauceri, D., Freitag, H. E., Oliveira, A. M., Bengtson, C. P., & Bading, H. (2011). Nuclear calcium-VEGFD signaling controls maintenance of dendrite arborization necessary for memory formation. Neuron, 71(1), 117–130. https://doi.org/10.1016/j.neuron.2011.04.022.CrossRefPubMed

McManus, R. M., Finucane, O. M., Wilk, M. M., Mills, K. H. G., & Lynch, M. A. (2017). FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology, 12(4), 670–681. https://doi.org/10.1007/s11481-017-9753-6.CrossRef

Mendell, J., Al-Zaidy, S. A., Shell, R., et al. (2017). AVXS-101 phase 1 gene therapy clinical trial in SMA type 1: Event free survival and achievement of developmental milestones [abstract]. Neurology, 88(16 suppl), CT.003.

Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., & Proia, R. L. (2005). Essential role for sphingosine kinases in neural and vascular development. Molecular and Cellular Biology, 25(24), 11113–11121. https://doi.org/10.1128/MCB.25.24.11113-11121.2005.CrossRefPubMedPubMedCentral

Montarolo, F., Perga, S., Martire, S., Navone, D. N., Marchet, A., Leotta, D., et al. (2016). Altered NR4A subfamily gene expression level in peripheral blood of Parkinson’s and Alzheimer’s disease patients. Neurotoxicity Research, 30(3), 338–344. https://doi.org/10.1007/s12640-016-9626-4.CrossRefPubMed

Munoz, L., & Ammit, A. J. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology, 58(3), 561–568. https://doi.org/10.1016/j.neuropharm.2009.11.010.CrossRefPubMed

Nazari, M., Keshavarz, S., Rafati, A., Namavar, M. R., & Haghani, M. (2016). Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. Brain Research Bulletin, 124, 95–102. https://doi.org/10.1016/j.brainresbull.2016.04.004.CrossRefPubMed

Nishihara, H., Shimizu, F., Sano, Y., Takeshita, Y., Maeda, T., Abe, M., et al. (2015). Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. PLoS ONE, 10(3), e0121488. https://doi.org/10.1371/journal.pone.0121488.CrossRefPubMedPubMedCentral

Olsen, A. S. B., & Faergeman, N. J. (2017). Sphingolipids: Membrane microdomains in brain development, function and neurological diseases. Open Biology,. https://doi.org/10.1098/rsob.170069.CrossRefPubMedPubMedCentral

Pruett, S. T., Bushnev, A., Hagedorn, K., Adiga, M., Haynes, C. A., Sullards, M. C., et al. (2008). Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. Journal of Lipid Research, 49(8), 1621–1639. https://doi.org/10.1194/jlr.R800012-JLR200.CrossRefPubMedPubMedCentral

Qin, C., Fan, W. H., Liu, Q., Shang, K., Murugan, M., Wu, L. J., et al. (2017). Fingolimod protects against ischemic white matter damage by modulating microglia toward M2 polarization via STAT3 pathway. Stroke, 48(12), 3336–3346. https://doi.org/10.1161/STROKEAHA.117.018505.CrossRefPubMedPubMedCentral

Ruiz, A., Joshi, P., Mastrangelo, R., Francolini, M., Verderio, C., & Matteoli, M. (2014). Testing Abeta toxicity on primary CNS cultures using drug-screening microfluidic chips. Lab on a Chip, 14(15), 2860–2866. https://doi.org/10.1039/c4lc00174e.CrossRefPubMed

Sanabria-Castro, A., Alvarado-Echeverria, I., & Monge-Bonilla, C. (2017). Molecular pathogenesis of Alzheimer’s disease: An update. Annals of Neurosciences, 24(1), 46–54. https://doi.org/10.1159/000464422.CrossRefPubMedPubMedCentral

Sawikr, Y., Yarla, N. S., Peluso, I., Kamal, M. A., Aliev, G., & Bishayee, A. (2017). Neuroinflammation in Alzheimer’s disease: The preventive and therapeutic potential of polyphenolic nutraceuticals. Advances in Protein Chemistry and Structural Biology, 108, 33–57. https://doi.org/10.1016/bs.apcsb.2017.02.001.CrossRefPubMed

Scarpini, E., Scheltens, P., & Feldman, H. (2003). Treatment of Alzheimer’s disease: Current status and new perspectives. The Lancet. Neurology, 2(9), 539–547. https://doi.org/10.1016/S1474-4422(03)00502-7.CrossRefPubMed

Shen, H., Kihara, T., Hongo, H., Wu, X., Kem, W. R., Shimohama, S., et al. (2010). Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. British Journal of Pharmacology, 161(1), 127–139. https://doi.org/10.1111/j.1476-5381.2010.00894.x.CrossRefPubMedPubMedCentral

Shen, W., Proost, P., Li, B., Gong, W., Le, Y., Sargeant, R., et al. (2000). Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR73 and attenuates cell responses to selected chemokines. Biochemical and Biophysical Research Communication, 272(1), 276–283. https://doi.org/10.1006/bbrc.2000.2770.CrossRef

Simard, A. R., Soulet, D., Gowing, G., Julien, J. P., & Rivest, S. (2006). Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron, 49(4), 489–502. https://doi.org/10.1016/j.neuron.2006.01.022.CrossRefPubMed

Singer, B. A. (2013). Initiating oral fingolimod treatment in patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 6(4), 269–275. https://doi.org/10.1177/1756285613491520.CrossRefPubMedPubMedCentral

Snow, W. M., & Albensi, B. C. (2016). Neuronal gene targets of NF-kappaB and their dysregulation in Alzheimer’s disease. Frontiers in Molecular Neuroscience, 9, 118. https://doi.org/10.3389/fnmol.2016.00118.CrossRefPubMedPubMedCentral

Sternberg, Z., Kolb, C., Chadha, K., Nir, A., Nir, R., George, R., et al. (2018). Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients. Neuropharmacology, 130, 71–76. https://doi.org/10.1016/j.neuropharm.2017.11.047.CrossRefPubMed

Strader, C. R., Pearce, C. J., & Oberlies, N. H. (2011). Fingolimod (FTY720): A recently approved multiple sclerosis drug based on a fungal secondary metabolite. Journal of Natural Products, 74(4), 900–907. https://doi.org/10.1021/np2000528.CrossRefPubMed

Sun, X., Chen, W. D., & Wang, Y. D. (2015). beta-Amyloid: The key peptide in the pathogenesis of Alzheimer’s disease. Frontiers in Pharmacology, 6, 221. https://doi.org/10.3389/fphar.2015.00221.CrossRefPubMedPubMedCentral

Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., et al. (2011). BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. The Journal of Neuroscience: The Official Journal of the Society of Neuroscience, 31(18), 6850–6857. https://doi.org/10.1523/JNEUROSCI.6467-10.2011.CrossRef

Takasugi, N., Sasaki, T., Ebinuma, I., Osawa, S., Isshiki, H., Takeo, K., et al. (2013). FTY720/fingolimod, a sphingosine analogue, reduces amyloid-beta production in neurons. PLoS ONE, 8(5), e64050. https://doi.org/10.1371/journal.pone.0064050.CrossRefPubMedPubMedCentral

Tarassishin, L., Suh, H. S., & Lee, S. C. (2011). Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3 K/Akt pathway. Journal of Neuroinflammation, 8, 187. https://doi.org/10.1186/1742-2094-8-187.CrossRefPubMedPubMedCentral

Tonelli, F., Lim, K. G., Loveridge, C., Long, J., Pitson, S. M., Tigyi, G., et al. (2010). FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signaling, 22(10), 1536–1542. https://doi.org/10.1016/j.cellsig.2010.05.022.CrossRef

Van Brocklyn, J. R., & Williams, J. B. (2012). The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death. Comparative Biochemistry and Physiology: Part B, Biochemistry & Molecular Biology, 163(1), 26–36. https://doi.org/10.1016/j.cbpb.2012.05.006.CrossRef

Van Doorn, R., Van Horssen, J., Verzijl, D., Witte, M., Ronken, E., Van Het Hof, B., et al. (2010). Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia, 58(12), 1465–1476. https://doi.org/10.1002/glia.21021.CrossRefPubMed

van Doorn, R., Lopes Pinheiro, M. A., Kooij, G., Lakeman, K., van der Hof, B., van der Pol, S. M., et al. (2012). Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. Journal of Neuroinflammation, 9, 133. https://doi.org/10.1186/1742-2094-9-133.CrossRefPubMedPubMedCentral

van Sorge, N. M., & Doran, K. S. (2012). Defense at the border: The blood-brain barrier versus bacterial foreigners. Future Microbiology, 7(3), 383–394. https://doi.org/10.2217/fmb.12.1.CrossRefPubMedPubMedCentral

Yarza, R., Vela, S., Solas, M., & Ramirez, M. J. (2015). c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for Alzheimer’s disease. Frontiers in pharmacology, 6, 321. https://doi.org/10.3389/fphar.2015.00321.CrossRefPubMed

Yazawa, K., Kihara, T., Shen, H., Shimmyo, Y., Niidome, T., & Sugimoto, H. (2006). Distinct mechanisms underlie distinct polyphenol-induced neuroprotection. FEBS Letters, 580(28–29), 6623–6628. https://doi.org/10.1016/j.febslet.2006.11.011.CrossRefPubMed

Yoshii, F., Moriya, Y., Ohnuki, T., Ryo, M., & Takahashi, W. (2017). Neurological safety of fingolimod: An updated review. Clinical & Experimental Neuroimmunology, 8(3), 233–243. https://doi.org/10.1111/cen3.12397.CrossRef

Zenaro, E., Piacentino, G., & Constantin, G. (2017). The blood-brain barrier in Alzheimer’s disease. Neurobiology of Disease, 107, 41–56. https://doi.org/10.1016/j.nbd.2016.07.007.CrossRefPubMedPubMedCentral

Zhong, L., Jiang, X., Zhu, Z., Qin, H., Dinkins, M. B., Kong, J. N., et al. (2018). Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide. Glia, 67(3), 498–511. https://doi.org/10.1002/glia.23558.CrossRefPubMed

Title: Beneficial Effects of Fingolimod in Alzheimer’s Disease: Molecular Mechanisms and Therapeutic Potential
Authors: Efthalia Angelopoulou
Christina Piperi
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Alzheimer's Disease
Alzheimer's Disease
Fingolimod
Published in: NeuroMolecular Medicine / Issue 3/2019
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-019-08558-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Beneficial Effects of Fingolimod in Alzheimer’s Disease: Molecular Mechanisms and Therapeutic Potential

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

eIF2B Mutations Cause Mitochondrial Malfunction in Oligodendrocytes

Sideroflexin 3 is a Mitochondrial Protein Enriched in Neurons

Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice

Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson’s Disease

Tetramethylpyrazine Nitrone Reduces Oxidative Stress to Alleviate Cerebral Vasospasm in Experimental Subarachnoid Hemorrhage Models

Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson’s Disease: A Study from Eastern India